Literature DB >> 29974132

Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment.

David Krug1,2, René Baumann3, Wilfried Budach4, Jürgen Dunst3, Petra Feyer5, Rainer Fietkau6, Wulf Haase7, Wolfgang Harms8, Thomas Hehr9, Marc D Piroth10, Felix Sedlmayer11, Rainer Souchon12, Frederik Wenz13, Rolf Sauer6.   

Abstract

Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review summarizes important implications of NACT and treatment response on the risk of recurrence and locoregional multidisciplinary management from the standpoint of radiation oncology.

Entities:  

Keywords:  Neoadjuvant treatment; Neoplasm recurrence, local; Post-mastectomy radiotherapy; Regional nodal irradiation; Sentinel lymph node biopsy

Mesh：

Year:  2018        PMID： 29974132     DOI： 10.1007/s00066-018-1329-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


  38 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

Review 2.  Neoadjuvant chemotherapy for operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Br J Surg       Date:  2007-10       Impact factor: 6.939

3.  Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study.

Authors:  Amparo Garcia-Tejedor; Catalina Falo; Cecilia Quetglas; Teresa Soler; Belen Marqueta; Raul Ortega; Miguel Gil-Gil; Sonia Pernas; Eulalia Fernandez-Montolí; Maria J Pla; Anna Guma; Maite Bajen; Ana Benitez; Arantxa Eraso; Miriam Campos; Anna Petit; Jordi Ponce
Journal:  Int J Surg       Date:  2017-01-30       Impact factor: 6.071

Review 4.  Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.

Authors:  Alfredo Berruti; Vito Amoroso; Fabio Gallo; Valentina Bertaglia; Edda Simoncini; Rebecca Pedersini; Laura Ferrari; Alberto Bottini; Paolo Bruzzi; Maria Pia Sormani
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

5.  Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Jose Vila; Mediget Teshome; Susan L Tucker; Wendy A Woodward; Mariana Chavez-MacGregor; Kelly K Hunt; Elizabeth A Mittendorf
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

6.  Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy.

Authors:  Bas B Koolen; Renato A Valdés Olmos; Wouter V Vogel; Marie Jeanne T F D Vrancken Peeters; Sjoerd Rodenhuis; Emiel J Th Rutgers; Paula H M Elkhuizen
Journal:  Breast Cancer Res Treat       Date:  2013-09-04       Impact factor: 4.872

7.  Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.

Authors:  Pauline Gillon; Nathan Touati; Christel Breton-Callu; Leen Slaets; David Cameron; Hervé Bonnefoi
Journal:  Eur J Cancer       Date:  2017-05-18       Impact factor: 9.162

8.  Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.

Authors:  Mila Donker; Marieke E Straver; Jelle Wesseling; Claudette E Loo; Margaret Schot; Caroline A Drukker; Harm van Tinteren; Gabe S Sonke; Emiel J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

9.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

10.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272
View more
  7 in total

Review 1.  Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer : Indication and technical considerations.

Authors:  Thomas Hehr; René Baumann; Wilfried Budach; Marciana-Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; David Krug; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederick Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2019-08-26       Impact factor: 3.621

2.  Impact of surface-guided positioning on the use of portal imaging and initial set-up duration in breast cancer patients.

Authors:  Montserrat Pazos; Franziska Walter; Daniel Reitz; Stephan Schönecker; Dinah Konnerth; Annemarie Schäfer; Maya Rottler; Filippo Alongi; Philipp Freislederer; Maximilian Niyazi; Claus Belka; Stefanie Corradini
Journal:  Strahlenther Onkol       Date:  2019-07-22       Impact factor: 3.621

3.  Prone versus supine free-breathing for right-sided whole breast radiotherapy.

Authors:  Odile Fargier-Bochaton; Xinzhuo Wang; Giovanna Dipasquale; Mohamed Laouiti; Melpomeni Kountouri; Olena Gorobets; Nam P Nguyen; Raymond Miralbell; Vincent Vinh-Hung
Journal:  Sci Rep       Date:  2022-01-11       Impact factor: 4.379

Review 4.  Post-Neoadjuvant Treatment Strategies in Breast Cancer.

Authors:  Christiane Matuschek; Danny Jazmati; Edwin Bölke; Bálint Tamaskovics; Stefanie Corradini; Wilfried Budach; David Krug; Svjetlana Mohrmann; Eugen Ruckhäberle; Tanja Fehm; Carolin Nestle Krämling; Markus Dommach; Jan Haussmann
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

Review 5.  Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review.

Authors:  David Krug; René Baumann; Wilfried Budach; Marciana Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer
Journal:  Breast Care (Basel)       Date:  2020-01-24       Impact factor: 2.860

6.  Early Prediction of Breast Cancer Recurrence for Patients Treated with Neoadjuvant Chemotherapy: A Transfer Learning Approach on DCE-MRIs.

Authors:  Maria Colomba Comes; Daniele La Forgia; Vittorio Didonna; Annarita Fanizzi; Francesco Giotta; Agnese Latorre; Eugenio Martinelli; Arianna Mencattini; Angelo Virgilio Paradiso; Pasquale Tamborra; Antonella Terenzio; Alfredo Zito; Vito Lorusso; Raffaella Massafra
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 7.  Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?

Authors:  Marc D Piroth; David Krug; Felix Sedlmayer; Marciana-Nona Duma; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Rainer Souchon; Vratislav Strnad; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2020-07-31       Impact factor: 3.621
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.